Published Date: 24 Apr 2023
Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
Cancer After Weight Loss; How Older Adults Use the Healthcare System.
2.
enhancing survivors of brain tumors' quality of life.
3.
Millions of men could benefit from faster scan to diagnose prostate cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
Approved BTK Inhibitor Without Covalent Bond for CLL.
1.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
2.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
3.
Glycopyrrolate: The Secret Weapon for Excessive Sweating
4.
Hematopoietic Aging Load and Disease Susceptibility: Mechanisms, Clinical Implications, and Management
5.
Circulating Tumor Cells & Platelet Interactions: Crosstalk for Therapeutic Advances
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation